A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1
A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg...
Read MoreSelect Page
Posted by Kidney Cancer Journal | Mar 2018
A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg...
Read MorePosted by Kidney Cancer Journal | Mar 2018
A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1 Abstract...
Read MorePosted by Kidney Cancer Journal | Nov 2017
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the...
Read MorePosted by Kidney Cancer Journal | Nov 2017
Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma...
Read MorePosted by Kidney Cancer Journal | Nov 2017
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review Abstract Checkpoint...
Read More